Evidence, Analysis & Scientific References

Technical Briefings, Case Studies & Scientific References

Expert analysis on landmark NDAs, emerging regulatory standards, and first-principles pharmaceutical science. This page also houses the peer-reviewed references and scientific literature underpinning our consulting capabilities. To see how these frameworks are applied in practice, visit our analytical tools or start a conversation.

CMC Fishbone Diagram

CMC Product Quality Fishbone Diagram for Pharma Development

Dissolution Response Surface

Dissolution Response Surface Plot for RTRT Strategy
Landmark Case Study

Architecting a Real-Time Release (RTRT) Strategy for a Modified Release NDA

Dissolution testing is traditionally a multi-day bottleneck in pharmaceutical manufacturing. For this modified-release solid oral drug, Cachet leadership engineered a Real-Time Release (RTRT) model that predicts dissolution based on critical upstream parameters.

The Breakthrough: Equipment Independence

Through advanced Design of Experiments (DOE), we identified that Tablet Hardness served as a sufficient proxy for both compression force and press speed.

SMC Formation Kinetics (F₀ = 16.72)

Succinylcholine Chloride (SCC) degradation kinetics by terminal sterilization

Thermal Degradation & Shelf-Life Impact

SCC shelf life stability and SMC formation

Predictive modeling confirms SMC exceeding the 2.0% USP limit during thermal stress.

Technical White Paper

The Sterilization Paradox of Succinylcholine Chloride (SCC)

Why Aseptic Processing trumps Terminal Sterilization for heat-unstable esters.

Regulatory bodies prioritize Terminal Sterilization (TS) whenever feasible. However, for Succinylcholine Chloride (SCC), achieving a 10-6 SAL requires thermal energy that triggers rapid hydrolytic degradation into Succinymonocholine (SMC).

Kinetic Barrier

Ea: 75–92 kJ/mol

Impurity Limit

USP SMC ≤ 2.0%

  • ● General Base Catalysis: Standard buffers accelerate ester cleavage during autoclaving.
  • ● Zero Margin: Cumulative thermal stress makes "Double-Sterilization" impossible.
DOWNLOAD White Paper (PDF)

✓ Your download has started successfully.

Scientific & Technical References

The following peer-reviewed literature, regulatory guidance documents, and technical standards underpin the consulting capabilities and analytical frameworks applied in every Cachet Pharma Consulting engagement.

Dissolution Science & Particle Size

  • Noyes, A.A., & Whitney, W.R. (1897). The rate of solution of solid substances in their own solutions. JACS. [Link]
  • Hixson, A.W., & Crowell, J.H. (1931). Dependence of reaction velocity upon surface and agitation. I&EC. [Link]
  • Aulton, M.E., & Taylor, K. (2017). Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. Elsevier. [Link]
  • FDA Guidance: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. [Link]
  • Moore, J.W., & Flanner, H.H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6): 64–74. [Original paper introducing f₁ and f₂.]
  • Shah, V.P., Tsong, Y., Sathe, P., & Liu, J.P. (1998). In vitro dissolution profile comparison — statistics and analysis of the similarity factor, f₂. Pharmaceutical Research, 15(6): 889–896.

Lyophilization & Sterile Processing

  • Tang, X., & Pikal, M.J. (2004). Design of freeze-drying processes for pharmaceuticals. Pharm Res. [Link]
  • Kasraian, K., & DeLuca, P.P. (1995). The effect of TBA on the resistance of the dry product layer. Pharm Res. [Link]
  • Franks, F. (1998). Freeze-drying of bioproducts: principles into practice. Eur J Pharm Biopharm. [Link]
  • Pikal, M.J. (1990). Freeze-drying of proteins. Part I: Process design. BioPharm.
  • ICH Q14: Analytical Procedure Development. International Council for Harmonisation, 2023. [Link]

Portfolio Optimization & Operational Excellence

  • Linear Programming: Dantzig, G.B. (1963). Linear Programming and Extensions. RAND. [Link]
  • Integer Programming: Wolsey, L.A. (2021). Integer Programming, 2nd ed. Wiley. [Link]
  • Portfolio Standards: PMI (2017). The Standard for Portfolio Management. [Link]
  • Resource Constraints: Goldratt, E.M. (1984). The Goal: A Process of Ongoing Improvement. [Link]

Regulatory Guidance & ICH Standards

  • FDA Guidance: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. CDER, August 1997. [Link]
  • ICH Q8(R2): Pharmaceutical Development. ICH Harmonised Guideline, 2009.
  • ICH Q9(R1): Quality Risk Management. ICH Harmonised Guideline, 2023.
  • ICH Q10: Pharmaceutical Quality System. ICH Harmonised Guideline, 2008.
  • ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. 2019.
  • European Medicines Agency. Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1. EMA, 2010.

Statistical Methods & Simulation

  • Gentle, J.E. (2003). Random Number Generation and Monte Carlo Methods. Springer. [Cholesky-based correlated simulation.]
  • Yuksel, N., Kanik, A.E., & Baykara, T. (2000). Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. Int J Pharm, 209(1–2): 57–67.
  • USP <711> Dissolution. United States Pharmacopeia. [Stage 1/2/3 acceptance criteria.]
  • Diggle, P.J., et al. (2002). Analysis of Longitudinal Data. Oxford University Press. [Correlated random effects modeling.]

Restructuring & Decommissioning

  • EHS Compliance: EPA. (2023). RCRA Orientation Manual. [Link]
  • Asset Recovery: ISPE. (2021). Good Practice Guide: Asset Management. [Link]
  • Human Capital: DOL. (2023). WARN Act Worker Transition Guide. [Link]
  • Site Safety: OSHA. (2022). Safety and Health Topics: Demolition and Decommissioning. [Link]

Regulatory Fluency & Defense

ICH Q8-Q12 21 CFR PART 4 ANNEX 1 ISO 13485